B&D White Capital Company’s AbbVie ABBV Stock Holding History

B&D White Capital Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$370K	Buy	+1,700	New	+$377K	0.05%	59
2025 Q3	–	Sell	-5,100	Closed	-$947K	–	75
2025 Q2	$947K	Buy	+5,100	New	+$948K	0.14%	57
2024 Q1	–	Sell	-70,273	Closed	-$10.9M	–	60
2023 Q4	$10.9M	Buy	+70,273	New	+$10.2M	3.39%	7
2023 Q3	–	Sell	-300,248	Closed	-$40.5M	–	67
2023 Q2	$40.5M	Buy	+300,248	New	+$44M	13.97%	1
2023 Q1	–	Sell	-11,500	Closed	-$1.86M	–	55
2022 Q4	$1.86M	Sell	11,500 -35,375	-75%	-$5.42M	0.46%	32
2022 Q3	$6.29M	Buy	46,875 +33,875	+261%	+$4.86M	2.35%	9
2022 Q2	$1.99M	Buy	13,000 +200	+2%	+$30.6K	0.85%	21
2022 Q1	$2.08M	Sell	12,800 -1,804	-12%	-$262K	0.66%	21
2021 Q4	$1.98M	Sell	14,604 -34,626	-70%	-$4.09M	0.65%	21
2021 Q3	$5.31M	Buy	49,230 +36,430	+285%	+$4.16M	2.04%	15
2021 Q2	$1.44M	Sell	12,800 -300	-2%	-$33.8K	0.64%	22
2021 Q1	$1.41M	Sell	13,100 -6,000	-31%	-$642K	0.75%	26
2020 Q4	$2.05M	Buy	+19,100	New	+$1.84M	1.16%	19

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

B&D White Capital Company's ABBV Position: Q1 2026 in Review

B&D White Capital Company opened a new position in AbbVie (ABBV) in Q1 2026: 1,700 shares worth $370K. The stake represents 0.05% of the portfolio and ranks #59 among its holdings. This is a return to the name: B&D White Capital Company previously reported a position in ABBV as recently as Q2 2025.

B&D White Capital Company first reported a position in ABBV in Q4 2020 and has held it in 13 quarters since. The position peaked at $40.5M in Q2 2023. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

B&D White Capital Company held 1,700 shares of AbbVie worth $370K as of Q1 2026.
AbbVie was a new B&D White Capital Company position in Q1 2026.
AbbVie made up 0.05% of B&D White Capital Company's portfolio in Q1 2026, its #59 holding.
B&D White Capital Company first reported a position in AbbVie in Q4 2020 and has held it in 13 quarters since.
B&D White Capital Company's AbbVie position peaked at $40.5M in Q2 2023.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on B&D White Capital Company's 13F filing for Q1 2026, filed 13 May 2026.